Search
Research
How many doses make a difference? An analysis of secondary prevention of rheumatic fever and rheumatic heart diseaseincreased adherence to penicillin prophylaxis is associated with reduced acute rheumatic fever recurrence and a likely reduction in mortality
Research
Status of research and development of vaccines for Streptococcus pyogenesVaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development
Research
Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's Northern TerritoryThis study adds to emerging data suggesting increasing importance of iGAS in low- and middle-income settings globally.
Research
Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical ConsiderationsA directed approach to the differential diagnosis of acute rheumatic fever now includes the concept of low-risk versus medium-to-high risk populations
Research
Screening for rheumatic heart disease: Quality and agreement of focused cardiac ultrasound by briefly trained health workersAfter brief training, health workers with no prior experience in echocardiography can obtain adequate quality images and make a reliable assessment
Research
Controlling acute rheumatic fever and rheumatic heart disease in developing countries: Are we getting closer?Improved opportunities for the primary prevention of ARF now exist, because of point-of-care antigen tests for Streptococcus pyogenes, and clinical decision...
Research
Global epidemiology of valvular heart diseaseValvular heart disease is a major contributor to loss of physical function, quality of life and longevity. The epidemiology of VHD varies substantially around the world, with a predominance of functional and degenerative disease in high-income countries, and a predominance of rheumatic heart disease in low-income and middle-income countries. Reflecting this distribution, rheumatic heart disease remains by far the most common manifestation of VHD worldwide and affects approximately 41 million people.
Research
Time to address the neglected burden of group A StreptococcusJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Housing Initiatives to Address Strep A Infections and Reduce RHD Risks in Remote Indigenous Communities in AustraliaAsha Rosemary Bowen Wyber BA MBBS DCH FRACP PhD GAICD FAHMS OAM MBChB MPH FRACGP PhD Head, Healthy Skin and ARF Prevention Senior Research Fellow
Research
Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...